194 433

Cited 0 times in

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

DC Field Value Language
dc.contributor.author김도영-
dc.date.accessioned2018-07-20T07:48:48Z-
dc.date.available2018-07-20T07:48:48Z-
dc.date.issued2017-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160549-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHCarcinoma, Hepatocellular*-
dc.subject.MESHHumans-
dc.subject.MESHInfusions, Intra-Arterial-
dc.subject.MESHLiver Neoplasms-
dc.subject.MESHPhenylurea Compounds*-
dc.titleCan metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorDo Young Kim-
dc.identifier.doi10.3350/cmh.2017.0107-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid28669140-
dc.subject.keywordHepatic arterial infusion chemotherapy-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordMetronomic chemotherapy-
dc.subject.keywordSorafenib-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.citation.volume23-
dc.citation.number2-
dc.citation.startPage123-
dc.citation.endPage124-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.23(2) : 123-124, 2017-
dc.identifier.rimsid44784-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.